A vial labeled "semaglutide" is only as useful to a research program as the data proving that's actually what it contains. Purity and identity testing are the two pieces of evidence that turn a label into something a lab can rely on, and they answer two different questions.
Purity: how much of the vial is semaglutide
High-performance liquid chromatography (HPLC) separates a sample's components by how they interact with a column under controlled solvent conditions, producing a chromatogram in which the target peptide appears as a defined peak. The area of that peak relative to the total signal gives a quantitative purity figure — commonly reported at 98% or higher for research-grade semaglutide. Smaller peaks elsewhere in the trace point to synthesis byproducts, truncated sequences, or degradation products that a simple visual inspection of powder could never reveal. A deeper walkthrough of this method is available at understanding HPLC purity analysis.
Identity: confirming it's semaglutide, not something similar
Purity alone doesn't confirm identity — a chromatographically clean sample could still be the wrong peptide. Mass spectrometry addresses that gap by measuring the molecular mass of the sample and comparing it against semaglutide's known formula, C187H291N45O59. A match within expected tolerance confirms the backbone sequence and the fatty-acid conjugate are both present and correctly assembled. The relationship between these two complementary methods is explained further in HPLC vs. mass spectrometry.
Other impurities worth checking for
Beyond the main purity figure, a thorough analytical package also looks at what's left behind from synthesis itself: residual trifluoroacetic acid (TFA) from cleavage and purification steps, residual solvents, and counter-ion content, all of which can affect a peptide's behavior in solution even when the primary HPLC peak looks clean. Acetate or TFA salt form, in particular, can influence solubility and apparent mass in downstream assays, which is one reason a complete COA reports more than a single purity percentage.
Tying results to the vial in hand
Because peptide synthesis is a batch process, results from one lot don't guarantee the same for the next. A batch-specific Certificate of Analysis (COA) links a particular set of HPLC and mass-spec results to the exact lot number on a vial, which is why COAs — rather than generic marketing claims — are the document researchers actually check. See how to read a COA for what each field means. Independent verification through third-party testing adds a further layer of assurance beyond a supplier's in-house results.
V8 Peptides documents semaglutide at ≥98% HPLC purity with a batch-specific COA available for every lot: semaglutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.